ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Virus-like Particles (VLPs) Vaccine Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-28I12661
Home | Market Reports | Health| Medical Devices & Equipment
Global Virus like Particles VLPs Vaccine Market Research Report 2023
BUY CHAPTERS

Global Virus-like Particles (VLPs) Vaccine Market Research Report 2025

Code: QYRE-Auto-28I12661
Report
May 2025
Pages:87
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Merck and Co.
GlaxoSmithKline PLC
Pfizer Inc
Dynavax Technologies
Sanofi
Wantai BioPharm
Serum Institute of India
Bharat Biotech
LG Chem
VBI Vaccines

Virus-like Particles (VLPs) Vaccine Market Size

The global market for Virus-like Particles (VLPs) Vaccine was valued at US$ 623 million in the year 2024 and is projected to reach a revised size of US$ 1087 million by 2031, growing at a CAGR of 8.4% during the forecast period.

Virus-like Particles (VLPs) Vaccine Market

Virus-like Particles (VLPs) Vaccine Market

VLP stands for virus-like particles. Virus-like particles are molecules that mimic viruses but are not infectious. They are a very effective way of creating vaccines against diseases such as human papillomavirus (HPV), hepatitis B, malaria, and more.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Virus-like Particles (VLPs) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus-like Particles (VLPs) Vaccine.
The Virus-like Particles (VLPs) Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Virus-like Particles (VLPs) Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Virus-like Particles (VLPs) Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Virus-like Particles (VLPs) Vaccine Market Report

Report Metric Details
Report Name Virus-like Particles (VLPs) Vaccine Market
Accounted market size in year US$ 623 million
Forecasted market size in 2031 US$ 1087 million
CAGR 8.4%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hepatitis
  • HPV
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck and Co., GlaxoSmithKline, Pfizer, Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India, Bharat Biotech, LG Chem, VBI Vaccines
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Virus-like Particles (VLPs) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Virus-like Particles (VLPs) Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Virus-like Particles (VLPs) Vaccine Market growing?

Ans: The Virus-like Particles (VLPs) Vaccine Market witnessing a CAGR of 8.4% during the forecast period 2025-2031.

What is the Virus-like Particles (VLPs) Vaccine Market size in 2031?

Ans: The Virus-like Particles (VLPs) Vaccine Market size in 2031 will be US$ 1087 million.

Who are the main players in the Virus-like Particles (VLPs) Vaccine Market report?

Ans: The main players in the Virus-like Particles (VLPs) Vaccine Market are Merck and Co., GlaxoSmithKline, Pfizer, Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India, Bharat Biotech, LG Chem, VBI Vaccines

What are the Application segmentation covered in the Virus-like Particles (VLPs) Vaccine Market report?

Ans: The Applications covered in the Virus-like Particles (VLPs) Vaccine Market report are Hepatitis, HPV, Others

What are the Type segmentation covered in the Virus-like Particles (VLPs) Vaccine Market report?

Ans: The Types covered in the Virus-like Particles (VLPs) Vaccine Market report are Live-Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Toxoid Vaccines

Recommended Reports

Vaccine Types

HPV & Related

Vaccine Delivery & Packaging

1 Virus-like Particles (VLPs) Vaccine Market Overview
1.1 Product Definition
1.2 Virus-like Particles (VLPs) Vaccine by Type
1.2.1 Global Virus-like Particles (VLPs) Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Live-Attenuated Vaccines
1.2.3 Inactivated Vaccines
1.2.4 Recombinant Vaccines
1.2.5 Toxoid Vaccines
1.3 Virus-like Particles (VLPs) Vaccine by Application
1.3.1 Global Virus-like Particles (VLPs) Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Hepatitis
1.3.3 HPV
1.3.4 Others
1.4 Global Virus-like Particles (VLPs) Vaccine Market Size Estimates and Forecasts
1.4.1 Global Virus-like Particles (VLPs) Vaccine Revenue 2020-2031
1.4.2 Global Virus-like Particles (VLPs) Vaccine Sales 2020-2031
1.4.3 Global Virus-like Particles (VLPs) Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Virus-like Particles (VLPs) Vaccine Market Competition by Manufacturers
2.1 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Virus-like Particles (VLPs) Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Virus-like Particles (VLPs) Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Virus-like Particles (VLPs) Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Virus-like Particles (VLPs) Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Virus-like Particles (VLPs) Vaccine, Date of Enter into This Industry
2.8 Global Virus-like Particles (VLPs) Vaccine Market Competitive Situation and Trends
2.8.1 Global Virus-like Particles (VLPs) Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Virus-like Particles (VLPs) Vaccine Players Market Share by Revenue
2.8.3 Global Virus-like Particles (VLPs) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Virus-like Particles (VLPs) Vaccine Market Scenario by Region
3.1 Global Virus-like Particles (VLPs) Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Virus-like Particles (VLPs) Vaccine Sales by Region: 2020-2031
3.2.1 Global Virus-like Particles (VLPs) Vaccine Sales by Region: 2020-2025
3.2.2 Global Virus-like Particles (VLPs) Vaccine Sales by Region: 2026-2031
3.3 Global Virus-like Particles (VLPs) Vaccine Revenue by Region: 2020-2031
3.3.1 Global Virus-like Particles (VLPs) Vaccine Revenue by Region: 2020-2025
3.3.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Region: 2026-2031
3.4 North America Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.4.1 North America Virus-like Particles (VLPs) Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Virus-like Particles (VLPs) Vaccine Sales by Country (2020-2031)
3.4.3 North America Virus-like Particles (VLPs) Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.5.1 Europe Virus-like Particles (VLPs) Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Virus-like Particles (VLPs) Vaccine Sales by Country (2020-2031)
3.5.3 Europe Virus-like Particles (VLPs) Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Virus-like Particles (VLPs) Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Virus-like Particles (VLPs) Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Virus-like Particles (VLPs) Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.7.1 Latin America Virus-like Particles (VLPs) Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Virus-like Particles (VLPs) Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Virus-like Particles (VLPs) Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Virus-like Particles (VLPs) Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Virus-like Particles (VLPs) Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Virus-like Particles (VLPs) Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Virus-like Particles (VLPs) Vaccine Sales by Type (2020-2031)
4.1.1 Global Virus-like Particles (VLPs) Vaccine Sales by Type (2020-2025)
4.1.2 Global Virus-like Particles (VLPs) Vaccine Sales by Type (2026-2031)
4.1.3 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Type (2020-2031)
4.2.1 Global Virus-like Particles (VLPs) Vaccine Revenue by Type (2020-2025)
4.2.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Type (2026-2031)
4.2.3 Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Virus-like Particles (VLPs) Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Virus-like Particles (VLPs) Vaccine Sales by Application (2020-2031)
5.1.1 Global Virus-like Particles (VLPs) Vaccine Sales by Application (2020-2025)
5.1.2 Global Virus-like Particles (VLPs) Vaccine Sales by Application (2026-2031)
5.1.3 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Application (2020-2031)
5.2.1 Global Virus-like Particles (VLPs) Vaccine Revenue by Application (2020-2025)
5.2.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Application (2026-2031)
5.2.3 Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Virus-like Particles (VLPs) Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck and Co.
6.1.1 Merck and Co. Company Information
6.1.2 Merck and Co. Description and Business Overview
6.1.3 Merck and Co. Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck and Co. Virus-like Particles (VLPs) Vaccine Product Portfolio
6.1.5 Merck and Co. Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Company Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Virus-like Particles (VLPs) Vaccine Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Dynavax Technologies
6.4.1 Dynavax Technologies Company Information
6.4.2 Dynavax Technologies Description and Business Overview
6.4.3 Dynavax Technologies Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Dynavax Technologies Virus-like Particles (VLPs) Vaccine Product Portfolio
6.4.5 Dynavax Technologies Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sanofi Virus-like Particles (VLPs) Vaccine Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Wantai BioPharm
6.6.1 Wantai BioPharm Company Information
6.6.2 Wantai BioPharm Description and Business Overview
6.6.3 Wantai BioPharm Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Wantai BioPharm Virus-like Particles (VLPs) Vaccine Product Portfolio
6.6.5 Wantai BioPharm Recent Developments/Updates
6.7 Serum Institute of India
6.7.1 Serum Institute of India Company Information
6.7.2 Serum Institute of India Description and Business Overview
6.7.3 Serum Institute of India Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Serum Institute of India Virus-like Particles (VLPs) Vaccine Product Portfolio
6.7.5 Serum Institute of India Recent Developments/Updates
6.8 Bharat Biotech
6.8.1 Bharat Biotech Company Information
6.8.2 Bharat Biotech Description and Business Overview
6.8.3 Bharat Biotech Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bharat Biotech Virus-like Particles (VLPs) Vaccine Product Portfolio
6.8.5 Bharat Biotech Recent Developments/Updates
6.9 LG Chem
6.9.1 LG Chem Company Information
6.9.2 LG Chem Description and Business Overview
6.9.3 LG Chem Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 LG Chem Virus-like Particles (VLPs) Vaccine Product Portfolio
6.9.5 LG Chem Recent Developments/Updates
6.10 VBI Vaccines
6.10.1 VBI Vaccines Company Information
6.10.2 VBI Vaccines Description and Business Overview
6.10.3 VBI Vaccines Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 VBI Vaccines Virus-like Particles (VLPs) Vaccine Product Portfolio
6.10.5 VBI Vaccines Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Virus-like Particles (VLPs) Vaccine Industry Chain Analysis
7.2 Virus-like Particles (VLPs) Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Virus-like Particles (VLPs) Vaccine Production Mode & Process Analysis
7.4 Virus-like Particles (VLPs) Vaccine Sales and Marketing
7.4.1 Virus-like Particles (VLPs) Vaccine Sales Channels
7.4.2 Virus-like Particles (VLPs) Vaccine Distributors
7.5 Virus-like Particles (VLPs) Vaccine Customer Analysis
8 Virus-like Particles (VLPs) Vaccine Market Dynamics
8.1 Virus-like Particles (VLPs) Vaccine Industry Trends
8.2 Virus-like Particles (VLPs) Vaccine Market Drivers
8.3 Virus-like Particles (VLPs) Vaccine Market Challenges
8.4 Virus-like Particles (VLPs) Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Merck and Co.
GlaxoSmithKline PLC
Pfizer Inc
Dynavax Technologies
Sanofi
Wantai BioPharm
Serum Institute of India
Bharat Biotech
LG Chem
VBI Vaccines
List of Tables
 Table 1. Global Virus-like Particles (VLPs) Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Virus-like Particles (VLPs) Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Virus-like Particles (VLPs) Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Virus-like Particles (VLPs) Vaccine Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Virus-like Particles (VLPs) Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Virus-like Particles (VLPs) Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Virus-like Particles (VLPs) Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Virus-like Particles (VLPs) Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Virus-like Particles (VLPs) Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Virus-like Particles (VLPs) Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Virus-like Particles (VLPs) Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Virus-like Particles (VLPs) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Virus-like Particles (VLPs) Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Virus-like Particles (VLPs) Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Virus-like Particles (VLPs) Vaccine Sales by Region (2020-2025) & (K Units)
 Table 18. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Virus-like Particles (VLPs) Vaccine Sales by Region (2026-2031) & (K Units)
 Table 20. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Virus-like Particles (VLPs) Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Virus-like Particles (VLPs) Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Virus-like Particles (VLPs) Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Virus-like Particles (VLPs) Vaccine Sales by Country (2020-2025) & (K Units)
 Table 27. North America Virus-like Particles (VLPs) Vaccine Sales by Country (2026-2031) & (K Units)
 Table 28. North America Virus-like Particles (VLPs) Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Virus-like Particles (VLPs) Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Virus-like Particles (VLPs) Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Virus-like Particles (VLPs) Vaccine Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Virus-like Particles (VLPs) Vaccine Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Virus-like Particles (VLPs) Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Virus-like Particles (VLPs) Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Virus-like Particles (VLPs) Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Virus-like Particles (VLPs) Vaccine Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Virus-like Particles (VLPs) Vaccine Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Virus-like Particles (VLPs) Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Virus-like Particles (VLPs) Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Virus-like Particles (VLPs) Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Virus-like Particles (VLPs) Vaccine Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Virus-like Particles (VLPs) Vaccine Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Virus-like Particles (VLPs) Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Virus-like Particles (VLPs) Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Virus-like Particles (VLPs) Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Virus-like Particles (VLPs) Vaccine Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Virus-like Particles (VLPs) Vaccine Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Virus-like Particles (VLPs) Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Virus-like Particles (VLPs) Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Virus-like Particles (VLPs) Vaccine Sales (K Units) by Type (2020-2025)
 Table 51. Global Virus-like Particles (VLPs) Vaccine Sales (K Units) by Type (2026-2031)
 Table 52. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Virus-like Particles (VLPs) Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Virus-like Particles (VLPs) Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Virus-like Particles (VLPs) Vaccine Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Virus-like Particles (VLPs) Vaccine Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Virus-like Particles (VLPs) Vaccine Sales (K Units) by Application (2020-2025)
 Table 61. Global Virus-like Particles (VLPs) Vaccine Sales (K Units) by Application (2026-2031)
 Table 62. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Virus-like Particles (VLPs) Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Virus-like Particles (VLPs) Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Virus-like Particles (VLPs) Vaccine Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Virus-like Particles (VLPs) Vaccine Price (US$/Unit) by Application (2026-2031)
 Table 70. Merck and Co. Company Information
 Table 71. Merck and Co. Description and Business Overview
 Table 72. Merck and Co. Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Merck and Co. Virus-like Particles (VLPs) Vaccine Product
 Table 74. Merck and Co. Recent Developments/Updates
 Table 75. GlaxoSmithKline Company Information
 Table 76. GlaxoSmithKline Description and Business Overview
 Table 77. GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Product
 Table 79. GlaxoSmithKline Recent Developments/Updates
 Table 80. Pfizer Company Information
 Table 81. Pfizer Description and Business Overview
 Table 82. Pfizer Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Pfizer Virus-like Particles (VLPs) Vaccine Product
 Table 84. Pfizer Recent Developments/Updates
 Table 85. Dynavax Technologies Company Information
 Table 86. Dynavax Technologies Description and Business Overview
 Table 87. Dynavax Technologies Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Dynavax Technologies Virus-like Particles (VLPs) Vaccine Product
 Table 89. Dynavax Technologies Recent Developments/Updates
 Table 90. Sanofi Company Information
 Table 91. Sanofi Description and Business Overview
 Table 92. Sanofi Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Sanofi Virus-like Particles (VLPs) Vaccine Product
 Table 94. Sanofi Recent Developments/Updates
 Table 95. Wantai BioPharm Company Information
 Table 96. Wantai BioPharm Description and Business Overview
 Table 97. Wantai BioPharm Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Wantai BioPharm Virus-like Particles (VLPs) Vaccine Product
 Table 99. Wantai BioPharm Recent Developments/Updates
 Table 100. Serum Institute of India Company Information
 Table 101. Serum Institute of India Description and Business Overview
 Table 102. Serum Institute of India Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Serum Institute of India Virus-like Particles (VLPs) Vaccine Product
 Table 104. Serum Institute of India Recent Developments/Updates
 Table 105. Bharat Biotech Company Information
 Table 106. Bharat Biotech Description and Business Overview
 Table 107. Bharat Biotech Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Bharat Biotech Virus-like Particles (VLPs) Vaccine Product
 Table 109. Bharat Biotech Recent Developments/Updates
 Table 110. LG Chem Company Information
 Table 111. LG Chem Description and Business Overview
 Table 112. LG Chem Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. LG Chem Virus-like Particles (VLPs) Vaccine Product
 Table 114. LG Chem Recent Developments/Updates
 Table 115. VBI Vaccines Company Information
 Table 116. VBI Vaccines Description and Business Overview
 Table 117. VBI Vaccines Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. VBI Vaccines Virus-like Particles (VLPs) Vaccine Product
 Table 119. VBI Vaccines Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Virus-like Particles (VLPs) Vaccine Distributors List
 Table 123. Virus-like Particles (VLPs) Vaccine Customers List
 Table 124. Virus-like Particles (VLPs) Vaccine Market Trends
 Table 125. Virus-like Particles (VLPs) Vaccine Market Drivers
 Table 126. Virus-like Particles (VLPs) Vaccine Market Challenges
 Table 127. Virus-like Particles (VLPs) Vaccine Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Virus-like Particles (VLPs) Vaccine
 Figure 2. Global Virus-like Particles (VLPs) Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Virus-like Particles (VLPs) Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Live-Attenuated Vaccines Product Picture
 Figure 5. Inactivated Vaccines Product Picture
 Figure 6. Recombinant Vaccines Product Picture
 Figure 7. Toxoid Vaccines Product Picture
 Figure 8. Global Virus-like Particles (VLPs) Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Virus-like Particles (VLPs) Vaccine Market Share by Application: 2024 & 2031
 Figure 10. Hepatitis
 Figure 11. HPV
 Figure 12. Others
 Figure 13. Global Virus-like Particles (VLPs) Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Virus-like Particles (VLPs) Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Virus-like Particles (VLPs) Vaccine Sales (2020-2031) & (K Units)
 Figure 16. Global Virus-like Particles (VLPs) Vaccine Average Price (US$/Unit) & (2020-2031)
 Figure 17. Virus-like Particles (VLPs) Vaccine Report Years Considered
 Figure 18. Virus-like Particles (VLPs) Vaccine Sales Share by Manufacturers in 2024
 Figure 19. Global Virus-like Particles (VLPs) Vaccine Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Virus-like Particles (VLPs) Vaccine Players: Market Share by Revenue in Virus-like Particles (VLPs) Vaccine in 2024
 Figure 21. Virus-like Particles (VLPs) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Virus-like Particles (VLPs) Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Virus-like Particles (VLPs) Vaccine Sales Market Share by Country (2020-2031)
 Figure 24. North America Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2020-2031)
 Figure 25. United States Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Virus-like Particles (VLPs) Vaccine Sales Market Share by Country (2020-2031)
 Figure 28. Europe Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Virus-like Particles (VLPs) Vaccine Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Virus-like Particles (VLPs) Vaccine Revenue Market Share by Region (2020-2031)
 Figure 36. China Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Virus-like Particles (VLPs) Vaccine Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Virus-like Particles (VLPs) Vaccine Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Virus-like Particles (VLPs) Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Virus-like Particles (VLPs) Vaccine by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Virus-like Particles (VLPs) Vaccine by Type (2020-2031)
 Figure 55. Global Virus-like Particles (VLPs) Vaccine Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Virus-like Particles (VLPs) Vaccine by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Virus-like Particles (VLPs) Vaccine by Application (2020-2031)
 Figure 58. Global Virus-like Particles (VLPs) Vaccine Price (US$/Unit) by Application (2020-2031)
 Figure 59. Virus-like Particles (VLPs) Vaccine Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Virus like Particle Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Virus like Particle VLP Service Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
VLP based Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Virus like Particle VLP Vaccines Market Research Report 2024
Global Virus like Particles VLPs Delivery System Market Research Report 2024
VLP Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
HPV Therapeutic Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
4 valent HPV Vaccine 4vHPV Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Virus Like Particles Market Research Report 2024
Bivalent HPV Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cervical Cancer Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Poliovirus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Human Papillomavirus 9 Valent Vaccine Market Research Report 2024
Global Viral Vector Vaccine for Humans Market Research Report 2024
Nanocarrier Based Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pseudovirus Products Market Research Report 2024
Gardasil HPV Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Porcine Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Polymer Nanoparticles PNP Formulation Development Market Research Report 2024
Human Papillomavirus Infection Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Surgical Waste Management Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-16G6108
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global PET-CT Scanning Services Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-27Q5892
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Micromanipulation Pipettes for IVF Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14K19926
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Nebulizer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-15N17310
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions